Irwin Mitchell's Corporate Team Advises On The Transaction For Pioneering Firm
The Corporate team at the London office of law firm Irwin Mitchell has advised on the flotation of Truspine Technologies plc on the Aquis Stock Exchange Growth Market.
Truspine Technologies is a medical device business in the spinal stabilisation market.
The company's devices represent a potential quantum shift in spinal fixation, fusion and laminoplasty techniques and it has developed three pioneering devices called Cervi-LOK (TM), GRASP Laminoplasty and Faci-LOK (TM).
Ian Roberts, CEO, commented: "We are very pleased with the level of interest generated from new investors in support of our admission to trading on AQSE. This IPO represents a landmark moment for Truspine and will enable our business to grow as we move towards achieving the necessary approvals for our unique suite of spinal (vertebral) stabilisation products. Our mission is to build a leading independent medical devices company that is at the forefront of reshaping the way clinicians approach spinal stabilisation and therefore alter and significantly improve how severe back pain is treated.
The market for spinal stabilisation is estimated at $10.2 billion globally and we are well positioned to disrupt this with our product range. The company's strategy is complemented by a first-class management team with a background in medical device manufacture, sales, distribution and marketing in addition to market disruption and taking products from an idea to a successful commercialisation."
Irwin Mitchell corporate partner, James Paton-Philip, acted for the Corporate Adviser, Cairn Financial Advisers, on the transaction. James was supported by colleagues Charlie Milsom and Christian Vale